18F-FAPI-04 PET/CT在宫颈癌患者评估中的应用:与18F-FDG PET/CT的头对头比较
纳入19例病理确诊宫颈癌患者,在7天内先后行18F-FDG PET/CT与18F-FAPI-04 PET/CT头对头比较。18F-FAPI-04检测原发灶19/19(100%)、转移淋巴结82枚(7例),均多于18F-FDG的18/19(95%)、44枚(7例);原发灶与转移淋巴结的靶本比显著更高。
要点
- 18F-FAPI-04 PET/CT检出原发灶19/19(100%),18F-FDG PET/CT检出18/19(95%)。
- 转移淋巴结:18F-FAPI-04检出82枚(7例),18F-FDG检出44枚(同7例)。
- 原发灶TBRblood 16.33 vs 9.83(P=0.005),TBRliver 21.59 vs 7.04(P<0.0001)。
核心结论
- 18F-FAPI-04 PET/CT在检测宫颈癌原发灶和转移淋巴结方面优于18F-FDG PET/CT。
- 18F-FAPI-04在正常组织中摄取较低,导致更高的靶本比。
- 这些发现提示18F-FAPI-04 PET/CT在宫颈癌中具有临床应用潜力。
研究设计与样本
- 22例病理确诊宫颈癌患者中19例(中位年龄62.3岁)纳入最终分析,在7天内行18F-FDG PET/CT与18F-FAPI-04 PET/CT。
- 比较两种显像剂检测原发灶和转移淋巴结的能力,并分析半定量PET/CT参数。
- 半定量参数包括SUVmax、SUVmean、代谢肿瘤体积(MTV,18F-FDG)和成纤维细胞肿瘤体积(FTV,18F-FAPI-04)、肿瘤病灶糖酵解(TLG,18F-FDG)和肿瘤病灶FAPI(TLF,18F-FAPI-04),以及靶本比(TBRliver和TBRblood,以病灶SUVmax除以正常肝或血池SUVmean计算)。
主要发现
- 18F-FAPI-04 PET/CT检出原发灶19/19(100%),18F-FDG PET/CT检出18/19(95%)。
- 两种显像剂PPV均为100%,18F-FDG PET/CT的NPV为0%。
- 转移淋巴结:18F-FAPI-04 PET/CT在7例患者中检出82枚,18F-FDG PET/CT在相同7例患者中检出44枚。
- 原发灶TBRblood:18F-FAPI-04 16.33 vs 18F-FDG 9.83(P=0.005);TBRliver:18F-FAPI-04 21.59 vs 18F-FDG 7.04(P<0.0001)。
- 转移淋巴结TBRblood:18F-FAPI-04 9.16 vs 18F-FDG 7.64(P=0.033);TBRliver:18F-FAPI-04 10.38 vs 18F-FDG 5.29(P<0.0001);其他半定量参数无显著差异。
临床怎么用
- 原文结论指出18F-FAPI-04 PET/CT在宫颈癌原发灶和转移淋巴结检测中表现优于18F-FDG PET/CT,并提示其具有临床应用潜力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To explore the potential utility of 18 F-AlF-NOTA-fibroblast activation protein inhibitor (FAPI)-04 PET/CT (denoted as 18 F-FAPI-04 PET/CT) in the evaluation of cervical cancer through a head-to-head comparison with 18 F-FDG PET/CT for detecting primary tumors and metastatic lymph nodes. PATIENTS AND METHODS: A total of 22 patients with a pathologic diagnosis of cervical cancer underwent 18 F-FDG PET/CT and 18 F-FAPI-04 PET/CT within a 7-day period. Out of the 22 patients, 19 (median age, 62.3 y) were included in the final analysis. Comparisons were made between the ability of 18 F-FDG PET/CT and 18 F-FAPI-04 PET/CT to detect primary lesions and metastatic lymph nodes; semiquantitative PET/CT parameters were also analyzed, including SUV max , SUV mean , metabolic tumor volume (MTV for 18 F-FDG) and fibroblast tumor volume (FTV for 18 F-FAPI-04), tumor lesion glycolysis (TLG for 18 F-FDG) and tumor lesion FAPI (TLF for 18 F-FAPI-04), and tumor-to-background ratios (TBR liver and TBR blood ), calculated by dividing the SUV max of the lesion by the SUV mean of normal liver or blood pool. RESULTS: 18 F-FAPI-04 PET/CT identified a greater number of primary lesions and metastatic lymph nodes compared with 18 F-FDG PET/CT. 18 F-FAPI-04 PET/CT detected 19/19 primary tumors, achieving a detection rate of 100%, while 18 F-FDG PET/CT identified 18/19 primary tumors, with a detection rate of 95%. The PPV for both tracers was 100%, the NPV for 18 F-FDG PET/CT was 0%. For metastatic lymph nodes, 18 F-FAPI-04 PET/CT detected 82 nodes in 7 patients, while 18 F-FDG PET/CT detected 44 nodes in the same 7 patients. TBR was significantly higher for 18 F-FAPI-04 PET/CT compared with 18 F-FDGPET/CT for primary lesions (TBR blood : 16.33 vs 9.83, P = 0.005; TBR liver : 21.59 vs 7.04, P < 0.0001) and metastatic lymph nodes (TBR blood : 9.16 vs 7.64, P = 0.033; TBR liver : 10.38 vs 5.29, P < 0.0001). No significant differences were observed in other semiquantitative parameters. CONCLUSIONS: 18 F-FAPI-04 PET/CT had superior performance in detecting primary lesions and metastatic lymph nodes in cervical cancer compared with 18 F-FDG PET/CT. 18 F-FAPI-04 exhibited lower uptake in normal tissues, leading to a higher TBR. These findings imply that 18 F-FAPI-04 PET/CT has potential for clinical application in cervical cancer.
引用
- Wei J, Zou K, Sun F, et al. 18 F-FAPI-04 PET/CT in the Evaluation of Patients With Cervical Cancers : Head-to-Head Comparison With 18 F-FDG PET/CT. Clin Nucl Med. 2025. PMID: 40902139. doi:10.1097/RLU.0000000000006103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。